Full-Time

Director – GCO Clinical Program Lead

GCO Clinical Program Lead, Early Phase

Posted on 5/9/2026

BeOne

BeOne

1,001-5,000 employees

Global oncology therapeutics discovery, development, manufacturing

Compensation Overview

$171.9k - $231.9k/yr

+ Annual Bonus + Incentive Compensation + Equity Awards + Employee Stock Purchase Plan

Remote in USA

Remote

Category
Biology & Biotech (1)
Required Skills
Google Cloud Platform
Requirements
  • Bachelor or higher degree in a scientific or healthcare discipline with 10+ years’ progressive experience in clinical trial industry
  • Proven project and program management experience in Early Phase clinical trials; First-In-Human experience favored
  • Proven project management exposure/experience across the entire lifecycle of multi-region/country clinical trials in a fast-paced global environment
  • Travel might be required as per business need
  • Computer Skills: Microsoft Office, Project Planning Applications, Clinical Trial Management Systems
Responsibilities
  • Strategic leadership and management: build, develop and retain the global team of gCSM, including hiring, training, mentoring, developing direct and indirect reports, performance appraisals and resource management
  • Oversee the delivery and goal achievement of projects within the designated program(s), serving as the point of escalation for resolving issues that gCSM cannot resolve
  • Collaborate with the other GCPLs and Franchise Heads to define and implement strategies and key priorities across-programs, and establish global standards for goals, performance measures, and capability development for the gCSM roles
  • GCO Representative for the designated Early Phase program(s)
  • In coordination with Franchise Head, accountable to the Franchise ERC, DCT and other governance teams as appropriate as GCO representative, to provide clinical operational insight to drive the program strategy and ensure excellence in execution
  • Lead/participate in the KOL engagement activities in the designated programs and may act as function spokesperson if needed
  • Evaluate and develop strategic feasibility and budget estimates during Early Planning for new CDPs and upon strategy change during the conduct of a study, where needed
  • Accountable for resource allocation and initiating CST formation; ensures appropriate transition of outputs from early planning to the gCSM
  • Create and be accountable for the annual program budget and resource forecasts, as well as contributing to and tracking the relevant DCT goals for the program
  • Create, review, and provide input to and maintain compound-level documents such as IB, DSUR, and protocol
  • Oversee timely, quality, and efficient study planning and execution of associated studies within the allocated program
  • Conduct regular program review meetings to mentor, support, and ensure all studies are tracking to the DCT/DRC-approved budget and timeline
  • Report on study status, goals, and operational KPIs, and enforce quality KPIs with support from the Compliance team
  • Collaborate with other GCPLs to evaluate and designate preferred global vendors and participate in vendor governance meetings
  • Create or review performance and development plans for direct reports, facilitate and support delivery of performance and development goals
  • Provide line management and mentorship to gCSMs working within the designated program(s)
  • Inspire and lead efforts to deepen scientific knowledge within the Clinical Operations’ function
  • Champions a global mindset and approach across Clinical Operations to foster collaboration and consistency across the organization
  • Provide expert knowledge on the execution of clinical trials through a deep understanding of ICH/GCP Guidelines and other applicable regulatory requirements
  • Point of escalation for all compound-related issues
  • Identify and drive process improvement initiatives in collaboration with Franchise Head and/or other GCPLs within program
  • Collaborates with cross-functional leaders to provide operational perspectives to enable effective and efficient delivery of clinical development goals
Desired Qualifications
  • Oncology experience preferred
  • Experience in both people management and program management preferred

BeOne Medicines develops and commercializes cancer therapies for patients worldwide, focusing on hematologic cancers and solid tumors. Its products, including Brukinsa, are sold globally and supported by licensing partnerships, with internal R&D and clinical development driving a broad late-stage pipeline. BeOne differentiates itself by leveraging a large-scale clinical trial network and cost-efficient global drug development to achieve high margins while pursuing large-market indications. The company aims to expand into immunology and solid tumors while maintaining strong investment in R&D to make high-impact, accessible oncology treatments available in more than 45 countries.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Dongcheng District, China

Founded

2010

Simplify Jobs

Simplify's Take

What believers are saying

  • TEVIMBRA Priority Review and Breakthrough Designation for HER2+ gastric cancer expands addressable market.
  • Q1 2026 revenue of $1.5B exceeds forecasts; BRUKINSA sales grew 38% year-over-year.
  • First GAAP profitability achieved in 2025 with $942M free cash flow generation.

What critics are saying

  • AbbVie's ABBV-599 Phase 3 readout H2 2026 directly challenges BRUKINSA's CLL dominance.
  • Merck's pembrolizumab FDA label expansion blocks TEVIMBRA's gastric cancer approval pathway.
  • Dr. Reddy's ibrutinib generic captures 15% CLL market share with 25% price discounts.

What makes BeOne unique

  • BRUKINSA demonstrates 74% six-year PFS and 84% OS in frontline CLL versus competitors.
  • Only BTK inhibitor showing superiority versus ibrutinib in head-to-head clinical trials.
  • Advanced ADC platform with multispecific antibodies and proprietary payload chemistry for tumor targeting.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at BeOne who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

401(k) Retirement Plan

Wellness Program

Paid Vacation

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-2%

2 year growth

5%
Yahoo Finance
Apr 10th, 2026
Amgen's lung cancer drug tarlatamab wins China approval, seen as $2B+ opportunity

Amgen's lung cancer drug tarlatamab has received approval from China's National Medical Products Administration, according to its development partner BeOne Medicines. The drug is a targeted immunotherapy for adults with extensive-stage small cell lung cancer that has progressed despite chemotherapy. Sold as Imdelltra in the US, tarlatamab is a bispecific antibody designed to connect cancer cells with immune cells, enabling the body's immune system to destroy the cancer. Neither Amgen nor Hong Kong-listed BeOne provided details on launch date or pricing for the Chinese market. Wall Street analysts estimate tarlatamab could generate annual sales exceeding $2 billion for Amgen.

Yahoo Finance
Feb 26th, 2026
BeOne Medicines reports $1.5B revenue, up 33% despite EPS miss in Q4

BeOne Medicines reported $1.5 billion in revenue for the quarter ended December 2025, a 32.8% year-over-year increase, beating the Zacks Consensus Estimate by 3.19%. The company posted earnings per share of $0.58, compared to a loss of $1.43 in the prior year, though this fell short of the $1.60 consensus estimate. Net product revenues reached $1.48 billion, exceeding the $1.45 billion analyst estimate. BRUKINSA generated $1.15 billion, surpassing the $1.09 billion estimate, whilst TEVIMBRA contributed $182 million, slightly below the $191.33 million forecast. The stock has returned 0.6% over the past month, matching the S&P 500's performance. BeOne currently holds a Zacks Rank of 2, indicating potential outperformance.

Business Wire
Feb 26th, 2026
BeOne Medicines reports $5.3B full-year revenue as BRUKINSA sales surge 49%

BeOne Medicines reported fourth quarter 2025 product revenues of $1.5 billion and full-year revenues of $5.3 billion, representing growth of 32% and 40% year-over-year respectively. Product revenue accounted for 99% of total revenue. BRUKINSA, the company's BTK inhibitor, achieved global sales of $1.1 billion in Q4 and $3.9 billion for the full year, up 38% and 49% respectively. US sales reached $845 million in Q4 and $2.8 billion annually. TEVIMBRA generated $182 million in Q4 and $737 million for the year. The company reported GAAP net income of $67 million in Q4 and $287 million for the full year, compared to losses in prior-year periods. Free cash flow reached $942 million for 2025, up $1.6 billion year-over-year. BeOne provided 2026 guidance of $6.2–6.4 billion in total revenue and $1.4–1.5 billion in non-GAAP operating income.

Yahoo Finance
Feb 2nd, 2026
BeOne Medicines trades at $340 with 51% annual return amid undervaluation signals

BeOne Medicines is trading at $340.38, representing a 9.44% year-to-date gain and 51.29% total shareholder return over the past year, though recent performance has been mixed with a one-day decline and flat weekly performance. The company appears undervalued against an estimated fair value of $401.52, based on strong revenue growth fundamentals. BeOne reported 41% year-over-year revenue growth in Q2 and raised full-year guidance to $5–5.3 billion, driven by demand for its oncology therapy BRUKINSA. The valuation narrative assumes continued aggressive expansion and rising profitability, supported by an ageing population and increased global healthcare spending. However, risks include potential competition affecting BRUKINSA revenues and possible delays in late-stage trials or regulatory approvals.

TipRanks
Nov 20th, 2025
BeOne Medicines Secures $1 Billion Financing Agreement - TipRanks.com

BeOne Medicines ( ($ONC) ) has shared an announcement. On November 13, 2025, BeOne Medicines Ltd. entered into a Facilities Agreement with HSBC and other financial ...